GEAR aims to extend these findings to the EDS/G-HSD population in an effort to reduce POTS-related symptoms, and thus potentially improve functional capacity and quality of life of those with EDS/G-HSD. This evidence concerns the gene CHST3 and Ehlers-Danlos syndrome.